Daily, Fri 20 Nov: Good fences make good neighbours? Washington's warning on China drug deals
Impossible d'ajouter des articles
Échec de l’élimination de la liste d'envies.
Impossible de suivre le podcast
Impossible de ne plus suivre le podcast
-
Lu par :
-
De :
A US congressional commission says licensing deals are sending money and know-how to Chinese biotechs. The same week, a Boston investor opened in Shanghai, and Novartis showcased a blood-pressure drug that started in Shanghai. The National Security Commission on Emerging Biotechnology analysed 57 deals between 15 of the biggest drugmakers in the US market and 42 Chinese biotechs from January 2023 to October 2026, and supports a proposed US Treasury outbound-investment rule under the COINS Act (comments close 7 December). Plus AbbVie's $40 million upfront for Cologne's DISCO Pharmaceuticals, set against the $650 million it paid in January for RemeGen's (荣昌生物) clinical-stage RC148 (not like-for-like); QCZ484 on Novartis's investor-day stage, which Argo Biopharma (舶望制药) says came from Argo in Shanghai under a licensing deal; Merck's research deal with Isomorphic Labs; a reported Sanofi look at Insmed; and a closed-loop brain stimulator for depression.
Full transcript and all sources for this episode
Both voices are AI-cloned. Basil Lui (X: @basillui) is the real person behind the show; Ning is an AI co-host. Personal views, not investment or medical advice. Basil has no personal holding in any company mentioned.
Weekly roundup: subscribe to The East-West Bio Brief newsletter on LinkedIn
Chapters
0:00 Intro and AI-voice disclosure
1:06 The commission's warning: 57 deals, earlier and bigger
3:58 The counterpoint: RA Capital's door in Shanghai
4:30 The price of early science: AbbVie, RemeGen and Starna
5:55 Quick hits: Novartis, Merck, Sanofi
8:33 Beyond biotech: a closed-loop brain stimulator
9:03 What to watch and sign-off
Key sources: NSCEB: 'Innovated in China: The PRC's Progress Towards Capturing the U.S. Pharmaceutical Market' (18 Nov 2026) · NSCEB: 'China is Closing the Biopharma Innovation Gap' (19 Nov 2026) · South China Morning Post: RA Capital opens Shanghai office (19 Nov 2026)
Also listen on: Apple Podcasts · Amazon Music · YouTube